Syrosingopine sensitizes cancer cells to killing by metformin

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Metformin, a common diabetes drug, exhibits anticancer properties.
• Syrosingopine's known mechanism involves vesicular monoamine transporters, but its role in potentiating metformin's anticancer activity is unexplored.

Purpose of the Study:

• To investigate the synergistic anticancer effect of combining metformin and syrosingopine.
• To elucidate the mechanism underlying this drug combination's efficacy.
• To assess the potential of this combination for cancer therapy.

Main Methods:

• In vitro binding assays to determine syrosingopine's interaction with glycolytic enzymes.
• Cell-based assays to evaluate the synergistic cytotoxicity of metformin and syrosingopine.
• Correlation analysis between enolase isoform expression and drug response.

Main Results:

• Syrosingopine significantly potentiates the anticancer activity of metformin through a synergistic effect.
• The observed synthetic lethality is specific to transformed cells and independent of vesicular monoamine transporter inhibition.
• Syrosingopine binds to α-enolase, and γ-enolase expression correlates with resistance to the drug combination.
• Cancer cells were sensitized to metformin and phenformin at sub-toxic concentrations of syrosingopine.

Conclusions:

• The combination of syrosingopine with metformin or phenformin represents a promising, synergistic therapeutic strategy for cancer treatment.
• Targeting α-enolase with syrosingopine enhances the efficacy of glycolytic inhibitors like metformin.
• This approach offers a novel strategy for overcoming drug resistance and improving cancer therapy outcomes.